| Literature DB >> 2544287 |
P Tfelt-Hansen1, J Brand, P Dano, A Doenicke, L J Findley, H K Iversen, D Melchart, H M Sahlender.
Abstract
In six European clinics 111 migraine patients were treated in a series of open dose-ranging studies with subcutaneous injections of 1 to 4 mg GR43175, a novel 5-HT 1-like receptor agonist. Response rates after 20-30 min were dose related and rose from 33% with 1 mg to 96% with 4 mg GR43175. Side effects were minor and transient. These promising results warrant confirmation in placebo-controlled double-blind trials. Migraine, treatment, 5-HT agonist, open studies.Entities:
Mesh：
Substances：
Year: 1989 PMID： 2544287 DOI： 10.1111/J.1468-2982.1989.TB00076.X
Source DB: PubMed Journal: Cephalalgia ISSN： 0333-1024 Impact factor: 6.292